Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the timeline for NICE guidance on the use of MTX110 for untreated diffuse intrinsic pontine glioma (DIPG) will be published.

The National Institute for Health and Care Excellence (NICE) plans to develop technology appraisal guidance for MTX110 but it is unable to advise on timescales. MTX110 does not currently have a United Kingdom marketing authorisation or licence for the treatment of diffuse intrinsic pontine glioma and is still undergoing phase one clinical trials. NICE can only appraise drugs that have a marketing authorisation for the treatment of a particular condition or are expected to receive one during the appraisal process and can only issue final guidance on drugs that have a marketing authorisation.